Oncology

Latest News

NSCLC | Image: Lung Cancer Foundation of America
Zongertinib Shows Durable Responses With No Interstitial Lung Disease in HER2-Mutated Advanced NSCLC

April 28th 2025

Results could give patients with HER2-mutated non–small cell lung cancer (NSCLC) an oral therapy option.

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com
Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

April 23rd 2025

Diabetes monitoring | Image credit: abidika - stock.adobe.com
New-Onset Type 2 Diabetes Linked to Higher Cancer Risk

April 23rd 2025

Vitamin D | Image credit: Galina Zhigalova - stock.adobe.com
Vitamin D’s Potential Role in Colorectal Cancer Prevention, Immune Health

April 23rd 2025

The study highlighted symptom patterns in the short-term preceding ED visits and unplanned hospitalizations using a previously validated natural language processing a pipeline. | Image credit: Tyler Olson - stock.adobe.com
Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities

April 22nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

USPSTF Releases Draft Recommendation on Drugs to Lower Risk of Breast Cancer
January 18th 2019

USPSTF Releases Draft Recommendation on Drugs to Lower Risk of Breast Cancer

Samantha DiGrande
Earlier this week, the US Preventive Services Task Force (USPSTF) released a draft guidance recommendations on medications for women at an increased risk for breast cancer.
Site Logo
January 18th 2019

Cost of Care: Biosimilars

Updates from the annual ASH meeting, December 2018.
Site Logo
January 18th 2019

Cost of Care

Updates from the annual ASH meeting, December 2018.
Site Logo
January 17th 2019

Clinical: Lymphoma

Updates from the annual ASH meeting, December 2018.
Site Logo
January 17th 2019

Clinical: Myelofibrosis

Updates from annual ASH meeting, December 2018.
Site Logo
January 17th 2019

Clinical: Chronic Lymphocytic Leukemia

Updates from the annual ASH meeting, December 2018.
Site Logo
January 17th 2019

Clinical: Multiple Myeloma

Updates from the annual ASH meeting, December 2018.
Site Logo
January 17th 2019

Clinical: CAR T-Cell Therapy

Updates from the Annual ASH meeting, December 2018.
African American Women Are at a Disadvantage in Preventing Breast Cancer
January 16th 2019

African American Women Are at a Disadvantage in Preventing Breast Cancer

Kelly Davio
Breast cancer risk estimation models identify women who are at high risk based on a variety of factors, and women who are identified as being at high risk may be able to reduce their chance of breast cancer through preventative measures such as prophylactic surgeries or chemoprevention medications. However, uptake of these preventative treatments varies among racial groups, new research from The Ohio State University finds that racial disparities in healthcare are to blame.
Comorbidities Impede Clinical Trial Participation Among Patients With Cancer
January 16th 2019

Comorbidities Impede Clinical Trial Participation Among Patients With Cancer

Jaime Rosenberg
Patients with cancer who have comorbidities are less likely to have clinical trial discussions, be offered a clinical trial, and participate in a clinical trial, according to a new study.
Podcast: This Week in Managed Care—Coverage From the JP Morgan Healthcare Conference and Other Health News
January 13th 2019

Podcast: This Week in Managed Care—Coverage From the JP Morgan Healthcare Conference and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
This Week in Managed Care: January 11, 2019
January 11th 2019

This Week in Managed Care: January 11, 2019

This week, the top managed care news included the FDA commissioner discussing boosting drug competition; BMS offering details on its acquisition of Celgene; and cancer mortality rates declining for the 25th consecutive year.
Cervical Cancer Screening Rates "Unacceptably Low," Researchers Find
January 10th 2019

Cervical Cancer Screening Rates "Unacceptably Low," Researchers Find

Jaime Rosenberg
Less than two-thirds of women aged 30 to 65 years were up to date with cervical cancer screenings in 2016. The percentage was even lower for women aged 21 to 29, with just over half up to date on screenings.
Cancer Mortality Rate Drops for the 25th Consecutive Year, but Socioeconomic Gap Widens
January 9th 2019

Cancer Mortality Rate Drops for the 25th Consecutive Year, but Socioeconomic Gap Widens

Kelly Davio
For the 25th consecutive year, the cancer mortality rate in the United States has declined, according to The American Cancer Society’s annual report on cancer rates and trends. The overall 27% drop in mortality rate translates into 2.6 million fewer deaths from cancer between the years 1991 and 2016.
What We're Reading: NYC Expands Health Coverage; Hospital Transparency Rule Confusion; Eli Lilly Purchases Loxo Oncology
January 9th 2019

What We're Reading: NYC Expands Health Coverage; Hospital Transparency Rule Confusion; Eli Lilly Purchases Loxo Oncology

AJMC Staff
New York City is expanding health coverage to 600,000 uninsured residents; a transparency rule requiring hospitals to post prices online is confusing patients; and Eli Lilly has purchased Loxo Oncology in what some are calling a massive bet on cancer genetic.
BMS, Celgene Discuss $74 Billion Acquisition During JP Morgan Healthcare Conference
January 8th 2019

BMS, Celgene Discuss $74 Billion Acquisition During JP Morgan Healthcare Conference

Jaime Rosenberg
Bristol-Meyers Squibb (BMS) and Celgene kicked off the 37th Annual JP Morgan Healthcare Conference by discussing their leading drugs, near-term launches, and early pipeline assets.
Dr Brian Koffman: It Is Critical That Patients Educate Themselves and Leverage Their Advantages
January 5th 2019

Dr Brian Koffman: It Is Critical That Patients Educate Themselves and Leverage Their Advantages

As a physician, Brian Koffman, MDCM, DCFP, DABFM, MS Ed, medical director, CLL Society, was able to leverage his medical and scientific knowledge during treatment for his chronic lymphocytic leukemia (CLL), and he encourages other patients to educate themselves on their illnesses in order to receive the best care.
Dr Sibel Blau Explains What the Results of OCM Have Shown
December 31st 2018

Dr Sibel Blau Explains What the Results of OCM Have Shown

Results from the first 2 performance periods of the Oncology Care Model (OCM) highlighted areas where Northwest Medical Specialties was doing well and areas it could improve, said Sibel Blau, MD, medical oncologist at Northwest Medical Specialties, PLLC.
Future of Therapy and Final Thoughts on Myelofibrosis
December 28th 2018

Future of Therapy and Final Thoughts on Myelofibrosis

Symptoms and Patient Progression
December 28th 2018

Symptoms and Patient Progression

Evolution of Myelofibrosis and Efficacy & Toxicity of Therapy
December 28th 2018

Evolution of Myelofibrosis and Efficacy & Toxicity of Therapy

Pacritinib and the Practical Implications
December 28th 2018

Pacritinib and the Practical Implications

Comparison of Ruxolitinib vs Fedratinib and Practical Implications
December 28th 2018

Comparison of Ruxolitinib vs Fedratinib and Practical Implications

Emerging Agents and Review of Fedratinib
December 28th 2018

Emerging Agents and Review of Fedratinib

Long-Term Survival and Adverse Effects With Ruxolitinib
December 28th 2018

Long-Term Survival and Adverse Effects With Ruxolitinib

Mechanism of JAK Inhibitors and a Review of Ruxolitinib
December 28th 2018

Mechanism of JAK Inhibitors and a Review of Ruxolitinib

NCCN Guidelines and Anemia Treatment
December 28th 2018

NCCN Guidelines and Anemia Treatment

Goals of Therapy and Starting Therapy for Myelofibrosis
December 28th 2018

Goals of Therapy and Starting Therapy for Myelofibrosis

Prognosis and Risk Stratification of Myelofibrosis
December 28th 2018

Prognosis and Risk Stratification of Myelofibrosis

Diagnosis of Myelofibrosis
December 28th 2018

Diagnosis of Myelofibrosis

<1
...
303132333435363738
...
184>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo